US equities
|
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Beam Therapeutics Inc. - Common Stock
(NQ:
BEAM
)
24.60
-0.17 (-0.69%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beam Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
September 16, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
September 08, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
September 01, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
August 31, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
August 04, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
July 23, 2026
Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
June 18, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
May 18, 2026
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity...
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
May 12, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 07, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
April 01, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
March 25, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
February 24, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
February 24, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
February 23, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
January 11, 2026
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
December 06, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
November 12, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
November 04, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
August 25, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
August 14, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
August 05, 2025
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
June 13, 2025
From
Beam Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
